<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184031</article-id><article-id pub-id-type="pmc">6122752</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0014</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Preventive Effect of Preoperative Vitamin D Supplementation on
Postoperative Atrial Fibrillation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Levent</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>&#x000d6;zcem</surname><given-names>Bar&#x000e7;&#x00131;n</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cerit</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Duygu</surname><given-names>Hamza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiology, Near East University, Nicosia,
Cyprus.</aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, Near East University,
Nicosia, Cyprus.</aff><aff id="aff3">
<label>3</label> Department of Pediatric Cardiology, Near East University, Nicosia,
Cyprus.</aff><author-notes><corresp id="c1">Correspondence Address: Levent Cerit, Near East University
Hospital, Near East Boulevard, Nicosia, Cyprus, Zip Code: 99138. E-mail:
<email>drcerit@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>347</fpage><lpage>352</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To assess the relationship between preoperative vitamin D (vitD)
supplementation and the development of postoperative atrial fibrillation
(POAF).</p></sec><sec><title>Methods</title><p>The study group consisted of 328 consecutive patients. The &#x00131;nfluence
of preoperative vitD supplementation on POAF was reviewed in 136 patients
who underwent coronary artery bypass graft surgery with vitD insufficiency
(n=80) and vitD deficiency (n=56). Patients were assigned to receive either
oral vitD (50.000 U) (treatment group, n=68) or not (control group, n=68) 48
hours before surgery. Patients were followed up during hospitalisation
process with respect to POAF.</p></sec><sec><title>Results</title><p>There was no significant difference between treatment and control groups with
regards to age, gender, diabetes mellitus, smoking history, chronic
obstructive pulmonary disease, left atrial diameter, and biochemical
parameters. Also, there was no significant difference between these groups
with regards to mean vitD level on both insufficiency and deficiency
patients (24.6&#x000b1;3.7 <italic>vs</italic>. 24.9&#x000b1;3.9 ng/ml
<italic>P</italic>=0.837, 11.4&#x000b1;4.9 <italic>vs</italic>.
10.9&#x000b1;5.2 ng/ml <italic>P</italic>=0.681, respectively). Although the
occurrence of POAF was not significantly different among treatment and
control groups in patients with vitD insufficiency (31% <italic>vs</italic>.
33% <italic>P</italic>=0.538), there was a significant difference between
the two groups regarding to POAF in patients with vitD deficiency (18%
<italic>vs</italic>. 29% <italic>P</italic>=0.02).</p></sec><sec><title>Conclusion</title><p>Although preoperative vitD supplementation was not found to be associated
with prevention of POAF in patients with vitD insufficiency, it was found to
be strongly associated with prevention of POAF in those with vitD
deficiency.</p></sec></abstract><kwd-group><kwd>Atrial Fibrillation</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Vitamin D</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACE-i/ARB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-converting
enzyme inhibitor/&#x000a0;</td><td rowspan="10" align="left" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hypertension</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">angiotensin receptor
blockers</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interleukin</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MPV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mean platelet
volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
graft</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">25-(OH)</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= 25-hydroxy (OH)</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COPD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic obstructive
pulmonary disease</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">POAF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Postoperative atrial
fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diabetes mellitus</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RAAS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Renin-angiotensin-aldosterone system</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Electrocardiogram</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RDW</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Red blood cell
distribution width</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heart failure</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TIA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transient ischemic
attack</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hyperlipidemia</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">vitD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Vitamin D</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Atrial fibrillation (AF) is the most common arrhythmia occurring after coronary
artery bypass graft (CABG) surgery and it is seen in approximately 15%-60% of these
patients. Postoperative AF (POAF) is associated with increased morbidity, mortality,
and longer hospital stay; it is also associated with a two-to-three-fold increase in
postoperative stroke. Ageing, obesity, hypertension (HT), prior AF, and heart
failure (HF) are found strongly associated with higher risk of
POAF<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>Vitamin D (vitD) has various cardiovascular pleiotropic effects by activating its
nuclear receptor in cardiomyocytes and vascular endothelial cells and by regulating
the renin-angiotensin-aldosterone system (RAAS), adiposity, and energy expenditure.
There is inconsistent data about the association between vitD and POAF. POAF
incidence was significantly higher in patients with vitD deficiency or insufficiency
than in patients with normal vitD level in previous studies<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r6" ref-type="bibr">6</xref>]</sup>. In our previous study, although there was a significant
negative correlation between vitD and left atrial diameter, the vitD level was not
an independent predictor of POAF<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>To the best of our knowledge, the relationship between preoperative vitD
supplementation in patients with vitD deficiency/insufficiency and POAF has not been
studied before. Therefore, we assessed the preventive effect of vitD supplementation
on POAF in patients who underwent CABG surgery with vitD
deficiency/insufficiency.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Our study was a randomised, blinded clinical trial. The study group consisted of 328
consecutive patients who underwent on-pump CABG surgery. Prevalence of vitD
insufficiency and deficiency found were 24.3% (n=80) and 17% (n=56) among the study
population, respectively. Patients were assigned to receive either oral vitD (50.000
IU) (treatment group; n=40 insufficiency patients, n=28 deficiency patients) or not
48 hours before CABG surgery. Patients were followed up during hospitalisation
process with respect to new-onset AF. All investigators were blinded to treatment
assignment. VitD supplementation was initiated in control group while discharging.
The patients' data were analysed for AF in the postoperative period until discharge.
The study was approved by the local ethics committee.</p><sec><title>Definition of POAF</title><p>The study's main outcome was the occurrence of POAF from surgery until hospital
discharge. Continuous electrocardiogram (ECG) monitoring was performed up to 48
hours after the operation to detect new-onset AF. Subsequently, telemetric ECG
device was placed on the patients until the fifth postoperative day. The
presence of ECG-documented AF for at least 5 min was recorded and analysed as
POAF without symptoms. All symptomatic episodes detected by the patients or
clinical residents were confirmed by a 12-lead ECG, and at least 1 min was
recorded and analysed as POAF. Patients who developed AF in the postoperative
period until discharge were included in the POAF group.</p><p>Patients who developed POAF were treated with intravenous beta-blocker as a
first-line rate control therapy. Intravenous amiodarone was initiated as a
first-line rhythm control therapy. If the heart rate was not tolerated despite
medical therapy (amiodarone, beta-blocker), electrical cardioversion was
performed if POAF had been occurred for &#x0003c;48 hours. If POAF had been occurred
for &#x02265;48 hours, left atrial clot was ruled out with transesophageal
echocardiography before electrical cardioversion. Anticoagulation therapy was
initiated in patients with POAF and continued for at least three months. The
decision to continue oral anticoagulation after three months was made according
to the CHA2DS2-VASC score [congestive HF, HT, age &#x02265;75 years (2
points), diabetes mellitus (DM), previous stroke/transient ischemic attack (TIA)
(2 points), vascular disease, age 65-74 years, and gender (female)].</p><p>Patient's data including age, gender, history of HT, hyperlipidemia (HL), chronic
kidney disease, DM, HF, chronic obstructive pulmonary disease (COPD), congenital
heart disease, valvular heart disease, liver disease, stroke, thyroid disease,
preoperative drug use [beta-blockers, diuretics, aspirin,
angiotensin-converting enzyme inhibitor/angiotensin receptor blockers
(ACE-i/ARB), and statins], echocardiographic variables such as ejection
fraction (EF) and left atrial diameter, and presence of valvular disease were
retrieved from the medical charts and included in the analysis.</p></sec><sec><title>Echocardiographic Examination</title><p>All patients underwent transthoracic echocardiography using Vivid S5 (GE
healthcare) echocardiography device and Mass S5 probe (2-4 MHz). Standard
two-dimensional and colour flow Doppler evaluation were acquired according to
the American Society of Echocardiography and European Society of
Echocardiography guidelines<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. EF was measured according to the Simpson's method.
Left atrial diameter was measured in parasternal long axis view using
two-dimensional echocardiography at the left ventricular end-systole.</p><p>The study's exclusion criteria were: patients with paroxysmal or persistent AF,
being on antiarrhythmic medications, patients who underwent pharmacological or
electrical cardioversion before CABG surgery due to reasons other than AF, and
patients who underwent other cardiac procedures in addition to CABG or who
planned to undergo emergency surgery. Furthermore, patients without vitD
insufficiency or deficiency were also excluded from the study.</p></sec><sec><title>Laboratory Tests</title><p>25-hydroxy (OH) vitD, calcium, and other biochemical and hematologic parameter
levels were measured following a fasting period of 8 hours. Serum 25-(OH) vitD
levels were measured by chemiluminescent immunoassay using a LIAISON analyser
(DiaSorin Inc). VitD deficiency was defined as serum levels of 25-(OH) vitD
&#x0003c;20 ng/ml. VitD insufficiency was defined as a level of 20-29 ng/ml. Plasma
levels of 25-(OH) vitD &#x0003e;30 ng/ml were defined as normal. Oral vitD
supplementation (50.000 U) was initiated 48 hours before CABG surgery.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using the SPSS (version 20.0, SPSS Inc.,
Chicago, IL, USA) software package. Continuous variables were expressed as mean
&#x000b1; standard deviation (mean&#x000b1; SD) and categorical variables were
expressed as a percentage (%). The Kolmogorov-Smirnov test was used to evaluate
variables distribution. Student's t-test was used to evaluate continuous
variables showing normal distribution and Mann-Whitney U-test was used to
evaluate variables that did not show normal distribution. A
<italic>P</italic>-value &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The present study included 328 consecutive patients, of which 80 (24.3%) patients had
vitD insufficiency and 56 (17%) had vitD deficiency. <xref rid="t1" ref-type="table">Table 1</xref> presents the main characteristics of the patients with and
without vitD supplementation. There was no significant difference between these two
groups with regards to age (63.8&#x000b1;9.3 years <italic>vs.</italic>
62.7&#x000b1;8.9 years, <italic>P</italic>=0.761), female gender (46.3%
<italic>vs.</italic> 48.1%, <italic>P</italic>=0.827), HT (62.5%
<italic>vs.</italic> 63.7%, <italic>P</italic>=0.834), DM (37.9%
<italic>vs.</italic> 35.4%, <italic>P</italic>=0.637), HL (32.8%
<italic>vs.</italic> 34.7%, <italic>P</italic>=0.682), smoking history (24.6%
<italic>vs.</italic> 27.1%, <italic>P</italic>=0.753), COPD (28.7%
<italic>vs.</italic> 26.9%, <italic>P</italic>=0.756), left atrial diameter
(38.9 mm <italic>vs.</italic> 39.3 mm, <italic>P</italic>=0.837), left ventricular
EF (62.7&#x000b1;6.9% <italic>vs.</italic> 61.3&#x000b1;7.1%,
<italic>P</italic>=0.843), and duration of hospitalization (8.1&#x000b1;2.3 days
<italic>vs.</italic> 7.9&#x000b1;2.1 days, <italic>P</italic>=0.891) (<xref rid="t1" ref-type="table">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient's characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Patient's characteristics</th><th align="center" colspan="2" rowspan="1">Vitamin D supplementation</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">(+)<break/>(n=68)</th><th align="center" rowspan="1" colspan="1">(-)<break/>(n=68)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">63.8&#x000b1;9.3</td><td align="center" rowspan="1" colspan="1">62.7&#x000b1;8.9</td><td align="center" rowspan="1" colspan="1">0.761</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender (%)</td><td align="center" rowspan="1" colspan="1">46.3</td><td align="center" rowspan="1" colspan="1">48.1</td><td align="center" rowspan="1" colspan="1">0.827</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">62.5</td><td align="center" rowspan="1" colspan="1">63.7</td><td align="center" rowspan="1" colspan="1">0.834</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (%)</td><td align="center" rowspan="1" colspan="1">37.9</td><td align="center" rowspan="1" colspan="1">35.4</td><td align="center" rowspan="1" colspan="1">0.637</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia (%)</td><td align="center" rowspan="1" colspan="1">32.8</td><td align="center" rowspan="1" colspan="1">34.7</td><td align="center" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking history (%)</td><td align="center" rowspan="1" colspan="1">24.6</td><td align="center" rowspan="1" colspan="1">27.1</td><td align="center" rowspan="1" colspan="1">0.753</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">28.7</td><td align="center" rowspan="1" colspan="1">26.9</td><td align="center" rowspan="1" colspan="1">0.756</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of hospitalization (days)</td><td align="center" rowspan="1" colspan="1">8.1&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">0.891</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricular ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">62.7&#x000b1;6.9</td><td align="center" rowspan="1" colspan="1">61.3&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">0.843</td></tr><tr><td align="left" rowspan="1" colspan="1">Left atrial diameter (mm)</td><td align="center" rowspan="1" colspan="1">38.9</td><td align="center" rowspan="1" colspan="1">39.3</td><td align="center" rowspan="1" colspan="1">0.837</td></tr><tr><td align="left" rowspan="1" colspan="1">Cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">74 (71.0-78.0)</td><td align="center" rowspan="1" colspan="1">75 (72-80)</td><td align="center" rowspan="1" colspan="1">0.672</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time (min)</td><td align="center" rowspan="1" colspan="1">96 (84.0-101)</td><td align="center" rowspan="1" colspan="1">94 (80.0-98.0)</td><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blocker therapy (%)</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">0.584</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin therapy (%)</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">0.783</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE-&#x00131;/ARB therapy (%)</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">0.867</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin therapy (%)</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">0.567</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretics therapy (%)</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">0.738</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ACE-&#x00131;/ARB=angiotensin-converting enzyme inhibitor/angiotensin
receptor blocker; COPD=chronic obstructive pulmonary disease</p></fn></table-wrap-foot></table-wrap><p>Also, there was no significant difference between these two groups with regards to
medications, such as beta-blockers (86% <italic>vs.</italic> 89%,
<italic>P</italic>=0.584), statin (92% <italic>vs.</italic> 94%,
<italic>P</italic>=0.783), ACE-&#x00131;/ARB (72% <italic>vs.</italic> 70%,
<italic>P</italic>=0.867), aspirin (96% <italic>vs.</italic> 93%,
<italic>P</italic>=0.567), and diuretics (23% <italic>vs.</italic>. 21%,
<italic>P</italic>=0.738) (<xref rid="t1" ref-type="table">Table 1</xref>). And
there was no significant difference between them with regards to cross-clamp time
(74 min <italic>vs.</italic> 75 min, <italic>P</italic>=0.672) and cardiopulmonary
bypass time (96 min <italic>vs.</italic> 94 min, <italic>P</italic>=0718) (<xref rid="t1" ref-type="table">Table 1</xref>).</p><p>In addition, there was no significant difference between these two groups with
regards to biochemical and haematological parameters, such as hemoglobin
(14.1&#x000b1;2.3 <italic>vs.</italic> 14.6&#x000b1;2.8 g/dl,
<italic>P</italic>=0.652), platelet (293.5&#x000b1;46.9 <italic>vs.</italic>
289.3&#x000b1;49.6 10<sup>3</sup>/&#x000b5;L, <italic>P</italic>=0.563), white blood
cell (7.9&#x000b1;3.7 <italic>vs.</italic> 8.2&#x000b1;3.4 10<sup>3</sup>/&#x000b5;L,
<italic>P</italic>=0.857), creatinine (1.03&#x000b1;0.29 <italic>vs.</italic>
1.01&#x000b1;0.23 mg/dl, <italic>P</italic>=0.761), fasting plasma glucose
(112.3&#x000b1;32.9 <italic>vs.</italic> 109.2&#x000b1;30.7 mg/dl, P=0.627),
C-reactive protein (1.14&#x000b1;0.92 <italic>vs.</italic> 1.22&#x000b1;0.91 mg/dl,
<italic>P</italic>=0.738), total cholesterol (186.3&#x000b1;43.1
<italic>vs.</italic> 181.3&#x000b1;44.9 mg/dl, <italic>P</italic>=0.613),
high-density lipoprotein (37.1&#x000b1;9.7 <italic>vs.</italic> 39.3&#x000b1;11.5
mg/dl, <italic>P</italic>=0.514), low-density lipoprotein (163.4&#x000b1;43.8 vs
165.9&#x000b1;45.7 mg/dl, <italic>P</italic>=0.628), and triglyceride
(183.1&#x000b1;56.7 <italic>vs.</italic> 178.1&#x000b1;54.7 mg/dl
<italic>P</italic>=0.485) (<xref rid="t2" ref-type="table">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Laboratory parameters.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Laboratory parameters</th><th align="center" colspan="2" rowspan="1">Vitamin D supplementation</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">(+)<break/>(n=68)</th><th align="center" rowspan="1" colspan="1">(-)<break/>(n=68)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">14.1&#x000b1;2.3 (14.7)</td><td align="center" rowspan="1" colspan="1">14.6&#x000b1;2.8 (14.9)</td><td align="center" rowspan="1" colspan="1">0.652</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet (10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">293.5&#x000b1;46.9 (302.8)</td><td align="center" rowspan="1" colspan="1">289.3&#x000b1;49.6 298.3)</td><td align="center" rowspan="1" colspan="1">0.563</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cell (10<sup>3</sup>/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;3.7 (8.7)</td><td align="center" rowspan="1" colspan="1">8.2&#x000b1;3.4 (8.9)</td><td align="center" rowspan="1" colspan="1">0.857</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.03&#x000b1;0.29 (1.12)</td><td align="center" rowspan="1" colspan="1">1.01&#x000b1;0.23 (1.08)</td><td align="center" rowspan="1" colspan="1">0.761</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mg/dl)</td><td align="center" rowspan="1" colspan="1">112.3&#x000b1;32.9 (104.6)</td><td align="center" rowspan="1" colspan="1">109.2&#x000b1;30.7 (106.9)</td><td align="center" rowspan="1" colspan="1">0.627</td></tr><tr><td align="left" rowspan="1" colspan="1">C-reactive protein (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.14&#x000b1;0.92 (0.97)</td><td align="center" rowspan="1" colspan="1">1.22&#x000b1;0.91 (0.99)</td><td align="center" rowspan="1" colspan="1">0.738</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mg/dl)</td><td align="center" rowspan="1" colspan="1">186.3&#x000b1;43.1 (195.1)</td><td align="center" rowspan="1" colspan="1">181.3&#x000b1;44.9 (192.7)</td><td align="center" rowspan="1" colspan="1">0.613</td></tr><tr><td align="left" rowspan="1" colspan="1">High-density lipoprotein (mg/dl)</td><td align="center" rowspan="1" colspan="1">37.1&#x000b1;9.7 (39.3)</td><td align="center" rowspan="1" colspan="1">39.3&#x000b1;11.5 (41.4)</td><td align="center" rowspan="1" colspan="1">0.514</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-density lipoprotein (mg/dl)</td><td align="center" rowspan="1" colspan="1">163.4&#x000b1;43.8 (184.2)</td><td align="center" rowspan="1" colspan="1">165.9&#x000b1;45.7 (182.7)</td><td align="center" rowspan="1" colspan="1">0.628</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride (mg/dl)</td><td align="center" rowspan="1" colspan="1">183.1&#x000b1;56.7 (192.6)</td><td align="center" rowspan="1" colspan="1">178.1&#x000b1;54.7 (189.4)</td><td align="center" rowspan="1" colspan="1">0.485</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin D level (deficiency group) (ng/ml)</td><td align="center" rowspan="1" colspan="1">11.4&#x000b1;4.9</td><td align="center" rowspan="1" colspan="1">10.9&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">0.681</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin D level (&#x00131;nsufficiency group)
(ng/ml)</td><td align="center" rowspan="1" colspan="1">24.6&#x000b1;3.7</td><td align="center" rowspan="1" colspan="1">24.9&#x000b1;3.9</td><td align="center" rowspan="1" colspan="1">0.837</td></tr></tbody></table></table-wrap><p>Regarding to mean vitD level of insufficiency (24.6&#x000b1;3.7 <italic>vs.</italic>
24.9&#x000b1;3.9 ng/ml, <italic>P</italic>=0.837) and deficiency patients
(11.4&#x000b1;4.9 <italic>vs.</italic> 10.9&#x000b1;5.2 ng/ml,
<italic>P</italic>=0.681), there was no significant difference between treatment and
control groups (<xref rid="t2" ref-type="table">Table 2</xref>).</p><p>Although the occurrence of POAF was not significantly different among treatment and
control groups in patients with vitD insufficiency (31% <italic>vs.</italic> 33%,
<italic>P</italic>=0.538), there was a significant difference between these two
groups with regards to POAF in patients with vitD deficiency (18%
<italic>vs.</italic> 29%, <italic>P</italic>=0.02) (<xref rid="t3" ref-type="table">Table 3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Prevalence of postoperative atrial fibrillation (POAF).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">&#x000a0;</th><th align="center" colspan="2" rowspan="1">Vitamin D supplementation</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1">(+)<break/>(n=68)</th><th align="center" rowspan="1" colspan="1">(-)<break/>(n=68)</th></tr></thead><tbody><tr><td align="center" rowspan="2" colspan="1">POAF (%)</td><td align="center" rowspan="1" colspan="1">Vitamin D insufficiency group, n (80)</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">0.538</td></tr><tr><td align="center" rowspan="1" colspan="1">Vitamin D deficiency group, n (56)</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">0.02</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This study demonstrated that preoperative vitD supplementation was significantly
preventive to the occurrence of POAF in patients with vitD deficiency while it was
not preventive to the occurrence of POAF in those with vitD insufficiency.
Beneficial effects of preoperative vitD supplementation might be associated with
tend to more occurrence of POAF in patients with vitD deficiency.</p><p>AF is the most common sustained arrhythmia and it has a major impact on the morbidity
and mortality of general population. The risk of AF increases up to 26% after the
age of 40. It is estimated that AF may account for 10% to 15% of all strokes, with
an associated mortality of up to 1.9-fold<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. In previous studies, ageing, male gender, COPD, HF,
DM, preoperative AF attacks, chronic renal disease, metabolic syndrome, increased
cross-clamp times, increased inflammatory markers, and left atrial diameter were
found to be independent variables predicting the development of
POAF<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Several potential mechanisms have described the association between vitD and
AF<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. VitD
insufficiency was associated with endothelial dysfunction and subclinical
atherosclerosis<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. VitD regulates inflammatory responses and up-regulates
the expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10) and
IL-6, according to in-vitro experiments<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Also, vitD regulates RAAS activity. Activated RAAS
can lead to an increase in new-onset AF<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. It is postulated that tissue RAAS can induce
apoptosis of cardiomyocytes and can contribute to changes in atrial
structure<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p><p>There were inconsistent results regarding low vitD levels and AF. Demir et
al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>
reported a strong relationship between vitD deficiency and non-valvular AF. Serum
vitD level was significantly associated with AF in Chinese patients with persistent
nonvalvular AF<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.
Hanafy et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>
revealed the direct electromechanical effects on the left atrium after vitD
administration and found that it could effectively prevent and terminate AF.</p><p>On the other hand, Rienstra et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> reported that vitD deficiency does not promote the
development of AF. Additionally, Qayyum et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> also showed that there was no significant
association between vitD deficiency and AF. Another prospective cohort study did not
support the hypothesis that vitD level is associated with AF<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>In the same manner, there were inconsistent results regarding preoperative serum vitD
level and POAF. POAF incidence was significantly higher in patients with vitD
deficiency or insufficiency than in patients with normal vitD level in previous
studies<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In our previous study,
although there was a significant negative correlation between vitD and left atrial
diameter, vitD level was not an independent predictor for POAF<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Several studies demonstrated that platelets play a critical and precipitating role in
AF occurrence as the volume and distribution width of platelets and the factors of
platelet activity appeared to be significantly higher in AF patients than in sinus
rhythm patients. Haematological indices red blood cell distribution width (RDW) and
mean platelet volume (MPV) are currently recognised as risk factors for POAF. MPV,
as a valuable haematological parameter in complete blood count test, could strongly
predict the occurrence of paroxysmal, persistent, or permanent AF<sup>[<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Our study did not include aforementioned
haematological parameters such as MPV and RDW. In our study, there was no
significant association between platelet count and POAF.</p><p>There are scarce data regarding the preventive role of preoperative vitD
supplementation on POAF in patients with vitD insufficiency and deficiency.
Therefore, we aimed to evaluate the preventive role of vitD supplementation. This
study revealed that preoperative vitD supplementation was significantly preventive
to the occurrence of POAF in patients with vitD deficiency while it was not
preventive to the occurrence of POAF in those with vitD insufficiency. Preventive
effect of vitD supplementation might be associated with direct electromechanical
effects on the left atrium, regulating RAAS and inflammatory responses. Further
randomised clinical studies with larger study population are needed in this
field.</p><sec><title>Limitations of the Study</title><p>Our study has some limitations: first, AF was diagnosed by ECG monitoring only
during hospitalisation process; second, this study has a small sample size;
third, vitD level was measured at a single point in time; fourth, the lack of
parathyroid hormone levels measurement; and fifth, the lack of haematological
markers such as MPV and RDW.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>To the best of our knowledge, this study is the first to evaluate the preventive
effect of vitD on POAF in patients with vitD insufficiency and deficiency. In this
study, preoperative vitD supplementation was found to be significantly preventive to
the occurrence of POAF in patients with vitD deficiency while it was not found to be
preventive to the occurrence of POAF in those with vitD insufficiency. VitD
deficiency should be considered in patients with POAF especially resistant to
medical and electrical cardioversion. Further prospective and randomised studies
with larger number of patients are required due to the relatively small number of
patients in the present study.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LC</td><td align="left" valign="top" rowspan="1" colspan="1">Conception of the work; acquisition,
analysis, and interpretation of data for the work, drafting the
work; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">B&#x000d6;</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition, analysis, and interpretation
of data for the work, drafting the work; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZC</td><td align="left" valign="top" rowspan="1" colspan="1">Conception of the work; acquisition,
analysis, and interpretation of data for the work, drafting the
work; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HD</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition, analysis, and interpretation
of data for the work, drafting the work; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Near East University Hospital, Near East Boulevard,
Nicosia, Cyprus.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filardo</surname><given-names>G</given-names></name><name><surname>Hamilton</surname><given-names>C</given-names></name><name><surname>Hebeler Jr</surname><given-names>RF</given-names></name><name><surname>Hamman</surname><given-names>B</given-names></name><name><surname>Grayburn</surname><given-names>P</given-names></name></person-group><article-title>New-onset postoperative atrial fibrillation after isolated
coronary artery bypass graft surgery and long-term survival</article-title><source>Circ Cardiovasc Qual Outcomes</source><year>2009</year><volume>2</volume><issue>3</issue><fpage>164</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">20031833</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gode</surname><given-names>S</given-names></name><name><surname>Aksu</surname><given-names>T</given-names></name><name><surname>Demirel</surname><given-names>A</given-names></name><name><surname>Sunbul</surname><given-names>M</given-names></name><name><surname>Gul</surname><given-names>M</given-names></name><name><surname>Bak&#x00131;r</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effect of vitamin D deficiency on the development of
postoperative atrial fibrillation in coronary artery bypass
patients</article-title><source>J Cardiovasc Thorac Res</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>140</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">28210468</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emren</surname><given-names>SV</given-names></name><name><surname>Aldemir</surname><given-names>M</given-names></name><name><surname>Ada</surname><given-names>F</given-names></name></person-group><article-title>Does deficiency of vitamin D &#x00131;ncrease new onset atrial
fibrillation after coronary artery bypass grafting surgery?</article-title><source>Heart Surg Forum</source><year>2016</year><volume>19</volume><issue>4</issue><fpage>E180</fpage><lpage>E184</lpage><pub-id pub-id-type="pmid">27585197</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerit</surname><given-names>L</given-names></name></person-group><article-title>Vitamin D as a modifiable risk factor for incident heart failure
in atrial fibrillation</article-title><source>JACC Heart Fail</source><year>2018</year><volume>6</volume><issue>1</issue><fpage>85</fpage><lpage>86</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerit</surname><given-names>L</given-names></name></person-group><article-title>Vitamin D as a predictor of postoperative atrial
fibrillation</article-title><source>Ann Thorac Surg</source><year>2017</year><volume>104</volume><issue>4</issue><fpage>1433</fpage><lpage>1433</lpage></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerit</surname><given-names>L</given-names></name></person-group><article-title>Postoperative atrial fibrillation and vitamin D</article-title><source>J Geriatr Cardiol</source><year>2016</year><volume>13</volume><issue>7</issue><fpage>643</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">27605948</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerit</surname><given-names>L</given-names></name><name><surname>Kemal</surname><given-names>H</given-names></name><name><surname>Gulsen</surname><given-names>K</given-names></name><name><surname>Ozcem</surname><given-names>B</given-names></name><name><surname>Cerit</surname><given-names>Z</given-names></name><name><surname>Duygu</surname><given-names>H</given-names></name></person-group><article-title>Relationship between vitamin D and the development of atrial
fibrillation after on-pump coronary artery bypass graft
surgery</article-title><source>Cardiovasc J Afr</source><year>2017</year><volume>28</volume><issue>2</issue><fpage>104</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">27701486</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>RM</given-names></name><name><surname>Bierig</surname><given-names>M</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Flachskampf</surname><given-names>FA</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><etal/><collab>American Society of Echocardiography's Nomenclature and Standards
Committee</collab><collab>Task Force on Chamber Quantification</collab><collab>American College of Cardiology Echocardiography Committee</collab><collab>American Heart Association</collab><collab>European Association of Echocardiography, European Society of
Cardiology</collab></person-group><article-title>Recommendations for chamber quantification</article-title><source>Eur J Echocardiogr</source><year>2006</year><volume>7</volume><issue>2</issue><fpage>79</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">16458610</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Manfreda</surname><given-names>J</given-names></name><name><surname>Tate</surname><given-names>RB</given-names></name><name><surname>Mathewson</surname><given-names>FA</given-names></name><name><surname>Cuddy</surname><given-names>TE</given-names></name></person-group><article-title>The natural history of atrial fibrillation: incidence, risk
factors and prognosis in the Manitoba follow-up study</article-title><source>Am J Med</source><year>1995</year><volume>98</volume><issue>5</issue><fpage>476</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">7733127</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banach</surname><given-names>M</given-names></name><name><surname>Rysz</surname><given-names>J</given-names></name><name><surname>Drozdz</surname><given-names>JA</given-names></name><name><surname>Okonski</surname><given-names>P</given-names></name><name><surname>Misztal</surname><given-names>M</given-names></name><name><surname>Barylski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Risk factors of atrial fibrillation following coronary artery
bypass grafting: a preliminary report</article-title><source>Circ J</source><year>2006</year><volume>70</volume><issue>4)</issue><fpage>438</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">16565561</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>LP</given-names></name><name><surname>Qiao</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cardiac hypertrophy in vitamin D receptor knockout mice: role of
the systemic and cardiac renin-angiotensin systems</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><issue>1</issue><fpage>E125</fpage><lpage>E132</lpage><pub-id pub-id-type="pmid">15367398</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oz</surname><given-names>F</given-names></name><name><surname>Cizgici</surname><given-names>AY</given-names></name><name><surname>Oflaz</surname><given-names>H</given-names></name><name><surname>Elitok</surname><given-names>A</given-names></name><name><surname>Karaayvaz</surname><given-names>EB</given-names></name><name><surname>Mercanoglu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of vitamin D insufficiency on the epicardial coronary flow
velocity and endothelial function</article-title><source>Coronary Artery Dis</source><year>2013</year><volume>24</volume><issue>5</issue><fpage>392</fpage><lpage>397</lpage></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canning</surname><given-names>MO</given-names></name><name><surname>Grotenhuis</surname><given-names>K</given-names></name><name><surname>Wit</surname><given-names>H</given-names></name><name><surname>Ruwhof</surname><given-names>C</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name></person-group><article-title>1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the
maturation of fully active immature dendritic cells from
monocytes</article-title><source>Eur J Endocrinol</source><year>2001</year><volume>145</volume><issue>3</issue><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">11517017</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frustaci</surname><given-names>A</given-names></name><name><surname>Chimenti</surname><given-names>C</given-names></name><name><surname>Bellocci</surname><given-names>F</given-names></name><name><surname>Morgante</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>MA</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Histological substrate of atrial biopsies in patients with lone
atrial fibrillation</article-title><source>Circulation</source><year>1997</year><volume>96</volume><issue>4</issue><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">9286947</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardin</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Thorin-Trescases</surname><given-names>N</given-names></name><name><surname>Leung</surname><given-names>TK</given-names></name><name><surname>Thorin</surname><given-names>E</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Evolution of the atrial fibrillation substrate in experimental
congestive heart failure: angiotensin-dependent and -independent
pathways</article-title><source>Cardiovasc Res</source><year>2003</year><volume>60</volume><issue>2</issue><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">14613861</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Uyan</surname><given-names>U</given-names></name><name><surname>Melek</surname><given-names>M</given-names></name></person-group><article-title>The effects of vitamin D deficiency on atrial
fibrillation</article-title><source>Clin Appl Thromb Hemost</source><year>2014</year><volume>20</volume><issue>1</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">22826443</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WR</given-names></name><name><surname>Liu</surname><given-names>ZY</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>DW</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Sha</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Relation of low vitamin D to nonvalvular persistent atrial
fibrillation in Chinese patients</article-title><source>Ann Noninvasive Electrocardiol</source><year>2014</year><volume>19</volume><issue>2</issue><fpage>166</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">24206389</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanafy</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>SL</given-names></name><name><surname>Lu</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Kao</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Electromechanical effects of 1,25-dihydroxyvitamin D with
antiatrial fibrillation activities</article-title><source>J Cardiovasc Electrophysiol</source><year>2014</year><volume>25</volume><issue>3</issue><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">24152033</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rienstra</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>McCabe</surname><given-names>EL</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Vitamin D status is not related to development of atrial
fibrillation in the community</article-title><source>Am Heart J</source><year>2011</year><volume>162</volume><issue>3</issue><fpage>538</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">21884873</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qayyum</surname><given-names>F</given-names></name><name><surname>Landex</surname><given-names>NL</given-names></name><name><surname>Agner</surname><given-names>BR</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>J&#x000f8;ns</surname><given-names>C</given-names></name><name><surname>Dixen</surname><given-names>U</given-names></name></person-group><article-title>Vitamin D deficiency is unrelated to type of atrial fibrillation
and its complications</article-title><source>Dan Med J</source><year>2012</year><volume>59</volume><issue>9</issue><elocation-id>A4505</elocation-id><pub-id pub-id-type="pmid">22951200</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitezova</surname><given-names>A</given-names></name><name><surname>Cartolano</surname><given-names>NS</given-names></name><name><surname>Heeringa</surname><given-names>J</given-names></name><name><surname>Zillikens</surname><given-names>MC</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><etal/></person-group><article-title>Vitamin D and the risk of atrial fibrillation: the Rotterdam
Study</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>5</issue><elocation-id>e0125161</elocation-id><pub-id pub-id-type="pmid">25933375</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weymann</surname><given-names>A</given-names></name><name><surname>Ali-Hasan-Al-Saegh</surname><given-names>S</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><name><surname>Popov</surname><given-names>AF</given-names></name><name><surname>Mirhosseini</surname><given-names>SJ</given-names></name><name><surname>Nombela-Franco</surname><given-names>L</given-names></name><etal/></person-group><article-title>Platelets cellular and functional characteristics in patients
with atrial fibrillation: a comprehensive meta-analysis and systematic
review</article-title><source>Med Sci Monit Basic Res</source><year>2017</year><volume>23</volume><fpage>58</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">28302997</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weymann</surname><given-names>A</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><name><surname>Ali-Hasan-Al-Saegh</surname><given-names>S</given-names></name><name><surname>Popov</surname><given-names>AF</given-names></name><name><surname>Jalil Mirhosseini</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>WL</given-names></name><etal/></person-group><article-title>Predictive role of coagulation, fibrinolytic, and endothelial
markers in patients with atrial fibrillation, stroke, and thromboembolism: a
meta-analysis, meta-regression, and systematic review</article-title><source>Med Sci Monit Basic Res</source><year>2017</year><volume>23</volume><fpage>97</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">28360407</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weymann</surname><given-names>A</given-names></name><name><surname>Ali-Hasan-Al-Saegh</surname><given-names>S</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><name><surname>Popov</surname><given-names>AF</given-names></name><name><surname>Mirhosseini</surname><given-names>SJ</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prediction of new-onset and recurrent atrial fibrillation by
complete blood count tests: a comprehensive systematic review with
meta-analysis</article-title><source>Med Sci Monit Basic Res</source><year>2017</year><volume>23</volume><fpage>179</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">28496093</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weymann</surname><given-names>A</given-names></name><name><surname>Ali-Hasan-Al-Saegh</surname><given-names>S</given-names></name><name><surname>Popov</surname><given-names>AF</given-names></name><name><surname>Sabashnikov</surname><given-names>A</given-names></name><name><surname>Mirhosseini</surname><given-names>SJ</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Haematological indices as predictors of atrial fibrillation
following isolated coronary artery bypass grafting, valvular surgery or
combined procedures: a systematic review with meta-analysis</article-title><source>Kardiol Pol</source><year>2018</year><volume>76</volume><issue>1</issue><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">28980298</pub-id></element-citation></ref></ref-list></back></article>